Hepatitis Delta: From pathogenesis to novel treatment options

Hosted by Sabela Lens

Prof. Dr. Heiner Wedemeyer is Director of the Clinic for Gastroenterology, Hepatology and Endocrinology at the MHH.

Heiner Wedemeyer studied medicine and musicology in Göttingen. Professor Wedemeyer completed his specialist training in the Clinic for Gastroenterology, Hepatology and Endocrinology at the Hannover Medical School. In 2012, he accepted the call for a W2 professorship for clinical infectiology in liver transplant recipients at the Hannover Medical School. In February 2018 he took up the W3 professorship for internal medicine, with a focus on gastroenterology and hepatology, at the University of Duisburg-Essen. On April 1, 2020, he moved from Essen to the Hannover Medical School as W3 professor and director of the clinic for gastroenterology, hepatology and endocrinology.

Scientifically, Heiner Wedemeyer focuses on inflammatory and viral diseases of the liver and gastrointestinal tract. From 1998 to 2000 he studied cellular immune responses in hepatitis C as part of a DFG-funded postgraduate fellowship at the National Institutes of Health in Bethesda, USA. From 2001 he headed a working group on cellular immunology in viral infections at the Hannover Medical School hepatitis. The scientific work of Professor Wedemeyer was or is funded by the German Research Foundation, the European Union, the BMBF and the Else Kröner-Fresenius Foundation. He is currently project manager in the Collaborative Research Center 900, in the German Center for Infection Research and in several BMBF-funded joint projects.

Heiner Wedemeyer played a decisive role in the scientific coordination of the Hepatitis Competence Network (since 2002) and in the activities of the German Liver Foundation (since 2006). He led the European Liver Society (EASL) as Secretary General from 2009 to 2011. Professor Wedemeyer was a working group leader in the creation of the national S3 guidelines for hepatitis B, hepatitis C and hepatocellular carcinoma as well as a panel member for various European Clinical Practice Guidelines of the EASL. He is currently Medical Director of Leberstiftung-GmbH Germany, which established the German Hepatitis C Registry, which, with more than 18,300 patients, represents one of the largest “real-world cohorts” for hepatitis C therapy worldwide.

Professor Wedemeyer has published more than 500 original papers and more than 130 reviews in high-ranking journals such as the New England Journal of Medicine, The Lancet, Lancet Infectious Diseases, Journal of Hepatology, Gastroenterology or Hepatology. He has also written more than 50 book chapters and co-edited 4 books. His current Hirsch Index is 103 (Google Scholar) and his publications have been cited more than 46,000 times. For his scientific work he has received the Hans Popper Award from the International Association for the Study of the Liver (2002), the Prevention Prize from the German Society for Internal Medicine (2008), the Innovation Prize from German University Medicine (2011), the Rudolph Schoen Prize (2011) and the EASL Registry Grant (2014).